Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant

[1]  G. Borgia,et al.  Successful treatment of post‐surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy , 2017, The Journal of antimicrobial chemotherapy.

[2]  Christina A. Sutherland,et al.  Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds , 2017, Antimicrobial Agents and Chemotherapy.

[3]  R. Bonomo,et al.  Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Woodford,et al.  Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles , 2017, The Journal of antimicrobial chemotherapy.

[5]  Christopher M. Bland,et al.  Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting , 2017, The Annals of pharmacotherapy.

[6]  A. Bogers,et al.  18F-FDG PET/CT in the Diagnosis and Management of Continuous Flow Left Ventricular Assist Device Infections: A Case Series and Review of the Literature , 2017, ASAIO journal.

[7]  Christina A. Sutherland,et al.  In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients , 2016, Infectious Diseases and Therapy.

[8]  Suzannah M. Schmidt-Malan,et al.  In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states. , 2016, Diagnostic microbiology and infectious disease.

[9]  D. Nicolau,et al.  Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen , 2016, Infectious Diseases and Therapy.

[10]  A. Oliver,et al.  Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC , 2014, Antimicrobial Agents and Chemotherapy.

[11]  L. Baddour,et al.  Clinical manifestations and management of left ventricular assist device-associated infections. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Karlowsky,et al.  Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli , 2013, Drugs.